Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Amishi Yogesh Shah"'
Autor:
Alice, Saji, Maneera, Chopra, Jake, Jacob, Mehmet, Altan, Omar, Alhalabi, Amishi Yogesh, Shah, Wei, Qiao, Yinghong, Wang, Anusha, Thomas
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can lead to GI toxicity, termed immune-mediated diarrhea and colitis (IMDC). Standardization of IMDC management and early GI consultation is imperative to control symptoms and
Autor:
Filip Janku, Matthew T. Campbell, Siqing Fu, Funda Meric-Bernstam, Timothy A. Yap, Andrew W. Hahn, Arlene O. Siefker-Radtke, Hung Le, Sarina Anne Piha-Paul, Vivek Subbiah, Nathaniel R. Wilson, Omar Alhalabi, Nizar M. Tannir, Kimberly Beltran, David S. Hong, Shubham Pant, Erick Campbell, Jianjun Gao, Janos Roszik, Pavlos Msaouel, Amishi Yogesh Shah, Aung Naing, Daniel D. Karp
Publikováno v:
Clinical Genitourinary Cancer. 20:e16-e24
Introduction Enrolling patients with metastatic urothelial carcinoma (mUC) in phase I trials provides an opportunity to identify biological drug activity. Developing prognostic scores may aid in patient selection for phase 1 trials. Patients and Meth
Publikováno v:
Kidney Cancer. 5:207-217
BACKGROUND: The introduction of immune checkpoint inhibitors rapidly changed treatment for patients with metastatic clear cell renal cell carcinoma (mRCC). First-line treatment now includes multiple immuno-oncology (IO) combinations that were approve
Autor:
Jennifer Wang, Amishi Yogesh Shah, Chad Tang, Quynh-Nhu Nguyen, Kanishka Sircar, Pavlos Msaouel, Surendra Prajapati, Zhiqian Yu, Steven Powell, Kieko Hara, Venus Le, Ravi Murthy, Haesun Choi, Seungtaek Choi, Prajnan Das, Khaja B Khan, Nizar M. Tannir, Eric Jonasch
Publikováno v:
The Lancet Oncology. 22:1732-1739
Summary Background The role of radiotherapy in metastatic renal cell carcinoma is controversial. We prospectively tested the feasibility and efficacy of radiotherapy to defer systemic therapy for patients with oligometastatic renal cell carcinoma. Me
Autor:
Alice Saji, Maneera Chopra, Jake Jacob, Mehmet Altan, Omar Alhalabi, Amishi Yogesh Shah, Wei Qiao, Yinghong Wang, Anusha Thomas
Purpose Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can lead to GI toxicity, termed immune mediated diarrhea and colitis (IMDC). Standardization of IMDC management and early GI consultation is imperative to control symp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf7c03810a3a93753165a2b02a15cf38
https://doi.org/10.21203/rs.3.rs-2216829/v1
https://doi.org/10.21203/rs.3.rs-2216829/v1
Autor:
Jose A. Karam, Pavlos Msaouel, Brian De, Matthew T. Campbell, Jennifer Wang, Christopher G. Wood, Surena F. Matin, Amishi Yogesh Shah, Andrew J. Bishop, Jing Li, Quynh Nhu Nguyen, Debra Nana Yeboa, Amado Zurita-Saavedra, Chad Tang, Aradhana M. Venkatesan, Eric Jonasch, Nizar M. Tannir, Amol J. Ghia
Publikováno v:
BJU Int
Objective To study whether delivering definitive radiotherapy to sites of oligoprogression in metastatic renal cell carcinoma enabled deferral of systemic therapy changes without compromising disease control or survival. Materials/methods We identifi
Autor:
David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu
Autor:
Sarina Anne Piha-Paul, Weijie Ma, Hamzah Abu-Sbeih, Jianbo Wang, John A. Thompson, Amishi Yogesh Shah, Fangwen Zou, Wei Qiao, Anusha Shirwaikar Thomas, Isabella C. Glitza Oliva, Hao Chi Zhang, Yinghong Wang, Yuanzun Peng
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:700-708
Background: Immune-mediated diarrhea and colitis (IMDC) is a common immune-related adverse effect related to immune checkpoint inhibitors. We aimed to identify risk factors for chronic IMDC and its prognostic value in cancer outcomes. Methods: We ret
Autor:
Amishi Yogesh Shah, Pavlos Msaouel, Siqing Fu, Hung Le, Timothy A. Yap, Vivek Subbiah, Sarina Anne Piha-Paul, Janku Filip, David S. Hong, Funda Meric-Bernstam, Erick Campbell, Alexander Y. Andreev-Drakhlin, Aung Naing, Matthew T. Campbell, Daniel D. Karp, Shubham Pant, Jianjun Gao, Jason Roszik, Arlene O. Siefker-Radtke, Andrew W. Hahn, Omar Alhalabi, Nizar M. Tannir
Publikováno v:
Molecular Cancer Research. 19:395-402
Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC) who participated in one
Autor:
Pavlos Msaouel, Sangeeta Goswami, Peter F. Thall, Xuemei Wang, Ying Yuan, Eric Jonasch, Jianjun Gao, Matthew T. Campbell, Amishi Yogesh Shah, Paul Gettys Corn, Alda L. Tam, Kamran Ahrar, Priya Rao, Kanishka Sircar, Lorenzo Cohen, Sreyashi Basu, Fei Duan, Sonali Jindal, Yuwei Zhang, Hong Chen, Shalini S. Yadav, Ronald Shazer, Hirak Der-Torossian, James P. Allison, Padmanee Sharma, Nizar M. Tannir
Publikováno v:
Science Translational Medicine. 14
The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitrava